Payment overview · 2025
General Payments
$491.17
36 reported records · 9 companies
Healthcare provider profile · identity verified
Seth Kleinbeck, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STUTTGART, AR · NPI 1912962143
Verified facts
What the public records show
CMS Open Payments records show Seth Kleinbeck, M.D. received $491.17 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 55.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $271.02 | 55.2% | 22 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $77.20 | 15.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.15 | 5.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.83 | 5.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.01 | 4.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.65 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.40 | 3.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.06 | 3.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.85 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $491.17 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $247.77 | 19 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $77.20 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.15 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.83 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.25 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $11.16 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 163 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 112 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 125 |
| Gabapentin | Gabapentin | 393 | 89 |
| Omeprazole | Omeprazole | 391 | 99 |
| Meloxicam | Meloxicam | 306 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 289 | 66 |
| Prednisone | Prednisone | 285 | 195 |
| Furosemide | Furosemide | 252 | 64 |
| Losartan Potassium | Losartan Potassium | 248 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 232 | 45 |
| Lisinopril | Lisinopril | 209 | 63 |
| Potassium Chloride | Potassium Chloride | 185 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 40 |
| Eliquis | Apixaban | 169 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 39 |
| Jardiance | Empagliflozin | 163 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 161 | 31 |
| Metformin Hcl | Metformin Hcl | 151 | 36 |
| Pregabalin | Pregabalin | 144 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 142 | 40 |
| Allopurinol | Allopurinol | 140 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 36 |
| Simvastatin | Simvastatin | 140 | 35 |
| Tramadol Hcl | Tramadol Hcl | 139 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 31 |
| Trazodone Hcl | Trazodone Hcl | 130 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 125 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 32 |
| Metformin Hcl Er | Metformin Hcl | 119 | 32 |
| Mounjaro | Tirzepatide | 112 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 23 |
| Xarelto | Rivaroxaban | 104 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 101 | 26 |
| Carvedilol | Carvedilol | 100 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 46 |
| Spironolactone | Spironolactone | 93 | 28 |
| Ondansetron Odt | Ondansetron | 92 | 34 |
| Famotidine | Famotidine | 91 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 19 |
| Ibuprofen | Ibuprofen | 81 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 61 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 14 |
| Olanzapine | Olanzapine | 69 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 15 |
| Ozempic | Semaglutide | 61 | 15 |
| Glipizide Er | Glipizide | 60 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 18 |
| Linzess | Linaclotide | 57 | 11 |
| Sertraline Hcl | Sertraline Hcl | 57 | 21 |
| Temazepam | Temazepam | 56 | 12 |
| Nifedipine Er | Nifedipine | 55 | 12 |
| Propranolol Hcl | Propranolol Hcl | 53 | 13 |
| Bupropion Xl | Bupropion Hcl | 52 | 13 |
| Buspirone Hcl | Buspirone Hcl | 47 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 12 |
| Fluconazole | Fluconazole | 46 | 40 |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Valsartan | Valsartan | 45 | 16 |
| Latanoprost | Latanoprost | 44 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 44 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 30 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 38 |
| Azelastine Hcl | Azelastine Hcl | 39 | 26 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Finasteride | Finasteride | 38 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 12 |
| Atenolol | Atenolol | 37 | 12 |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 11 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Nystatin | Nystatin | 30 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Baclofen | Baclofen | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 12 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 24 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 14 |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 14 |
| Glipizide | Glipizide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Naproxen | Naproxen | 12 | suppressed |
| Paricalcitol | Paricalcitol | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $491.17 · 36 records | ABBVIE INC. | AREXVY, BREZTRI, CAPLYTA, INTELLIS ADAPTIVESTIM, JARDIANCE, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error